The patient satisfaction survey results were based on the responses of the patients who completed the study: 35 patients in the pen group and 40 patients in the vial and syringe group. Demographic ...
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...